Nicholas Boston
@Highvista Strategies Llc
Latest period2024 - Q3ReportedManaged Assets$289.961MTotal holdings142
Assets growth rate5.92%Assets growth rate (2-Q avg)1.78%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Highvista Strategies Llc's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 142 positions.
Assets under management
The assets under management (AUM) of Highvista Strategies Llc over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 289.961M in assets, with a quarterly growth rate of 5.92% and a 2-quarter average growth rate of 1.78%. The portfolio is managed by Nicholas Boston, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
XENEXenon Pharmaceuticals Inc
| 1.01% | $2.904M 73,762 shares@ $39.38 avg price | Increased 1.44% |
ELVNEnliven Therapeutics Inc
| 1% | $2.872M 112,459 shares@ $25.55 avg price | Decreased -6.11% |
OLMAOlema Pharmaceuticals Inc
| 0.88% | $2.533M 212,185 shares@ $11.95 avg price | Decreased -14.4% |
RVMDRevolution Medicines Inc
| 0.87% | $2.52M 55,562 shares@ $45.36 avg price | Increased 38.62% |
COGTCogent Biosciences Inc
| 0.85% | $2.437M 225,633 shares@ $10.8 avg price | Decreased -19.73% |
EWTXEdgewise Therapeutics Inc
| 0.82% | $2.371M 88,838 shares@ $26.69 avg price | New Position |
DYNDyne Therapeutics Inc
| 0.82% | $2.352M 65,482 shares@ $35.92 avg price | New Position |
PFSIPennymac Finl Svcs Inc New
| 0.77% | $2.204M 19,337 shares@ $113.98 avg price | Increased 46.09% |
MLTXMoonlake Immunotherapeutics
| 0.76% | $2.195M 43,541 shares@ $50.42 avg price | Increased 3.06% |
BABAAlibaba Group Hldg Ltd
| 0.75% | $2.16M 20,357 shares@ $106.13 avg price | Increased 26.78% |